Investment Thesis
The coming weeks could unveil two new FDA approvals for Ultragenyx Pharmaceutical Inc. (RARE), boosting its efforts to sustain the growth momentum. Expecting the Phase 3 trial starts as early as this year, two more candidates are undergoing mid-stage studies with their interim data already showing positive results ahead of crucial data readouts in the months ahead. Marked by the lack of competition, the new indications could leverage the company's existing resources for an effective market launch, therefore minimizing the strain on the bottom-line. Meanwhile, using both conventional and unconventional means